Glutathione research and evidence overview

Glutathione is in an unusual position: its biochemistry is textbook material, while the reasons people actually buy it—skin lightening, anti-aging, "detox"—rest on a handful of small, short trials with mixed results. The honest summary is that oral glutathione at 250–500 mg per day has produced statistically significant but modest reductions in melanin index across several small randomized trials, that the effects fade after treatment stops, and that the injectable and intravenous versions—the forms most heavily marketed—have the least supporting data of any route studied.

As a molecule, glutathione is the principal intracellular antioxidant and a cofactor for glutathione peroxidase and the S-transferase enzymes that carry out phase II detoxification. That role is not in dispute. What is disputed is whether taking more of it changes anything measurable in a healthy person.

The most frequently cited human study is a 12-week, three-arm randomized controlled trial by Weschawalit and colleagues, published in Clinical, Cosmetic and Investigational Dermatology in 2017 (PMC5413479). Sixty healthy volunteers were enrolled and 57 completed, randomized to reduced glutathione (GSH) 250 mg/day, oxidized glutathione (GSSG) 250 mg/day, or placebo.

• Pigmentation — melanin index and UV spots trended downward in both glutathione arms relative to placebo, though the differences were not significant at every measurement site.
• Wrinkles — the GSH arm showed a significant reduction at the sun-protected arm site (p=0.006) and among participants over 40 (p=0.043).
• Elasticity — a non-significant tendency toward improvement in both glutathione arms.
• Safety — adverse events in 13.15% of treated participants, none serious.

The authors state the limitation plainly: every participant was female, Asian, and aged 20–50, over a single 12-week window. That is a narrow slice of the population to generalize from, and the endpoints were instrument readings rather than outcomes a person would necessarily notice.

A systematic review in the International Journal of Dermatology (PMID 39444151) pooled a decade of glutathione skin-lightening and melasma studies and graded them for level of evidence and risk of bias. Its findings sharpen the picture considerably:

• Five randomized controlled trials plus one open-arm study of oral glutathione (250 mg once daily, 250 mg twice daily, and 500 mg once daily) reported significant melanin-index reductions versus placebo.
• Topical glutathione at 0.5% outperformed both 0.1% and placebo; combining topical 2% with oral dosing beat either alone.
• Roughly equal numbers of included studies were rated low and high risk of bias—meaning the literature is not uniformly reliable.
• The reviewers describe the outcomes of both oral and topical routes as unsustainable: benefits do not persist once treatment stops.

Intravenous glutathione is the form most aggressively promoted in cosmetic settings and the one with the thinnest evidence. The same 2025 review found only a single placebo-controlled IV study, in which the response rate (6 of 16, 37.5%) did not reach significance against control (18.7%, p=0.054). On that basis the reviewers concluded that IV glutathione "is contraindicated due to lack of efficacy and side effects"—an unusually direct statement for a systematic review, and the opposite of how the route is marketed.

In the United States, glutathione is sold as a dietary supplement and is not an FDA-approved drug for antioxidant, anti-aging, or skin-lightening indications. Injectable and IV skin-lightening preparations are unapproved for those uses, and multiple national regulators have issued safety warnings about them.

Three questions separate a useful glutathione study from a promotional one: which route was tested (oral, topical, and IV produce different evidence), how long the follow-up ran after dosing ended, and whether the endpoint was a colorimeter reading or something a participant reported. Most of the positive data comes from small single-center trials in narrow populations, measured by instrument, over 8–12 weeks. That is real evidence, and it is also a long way from the transformations described in advertising.